A study published in Nature Medicine in November 2025 indicates that daily walking, even as few as 3,000 steps, may significantly slow the progression of Alzheimer's disease, reducing cognitive and functional decline by nearly 50%. This research offers a straightforward, accessible approach to potentially mitigate the disease's impact.

For individuals concerned about Alzheimer's disease, these findings suggest that increased physical activity could be a key lifestyle factor in delaying the onset or worsening of symptoms. The study highlights that significant benefits may be achievable with moderate daily walking, potentially delaying cognitive decline by several years.

What the records show

Key findings show that individuals walking 3,000 to 5,000 steps daily experienced an approximate three-year delay in cognitive decline. Those consistently walking between 5,000 and 7,500 steps per day saw an average delay of seven years. Optimal benefits were observed within the 5,000 to 7,500 step range, suggesting that the commonly promoted 10,000-step goal might not be necessary for these specific protective effects against Alzheimer's-related brain changes.

The study found that increased physical activity was linked to a reduction in harmful tau protein buildup in specific brain regions among participants who already had amyloid plaques. However, physical activity did not reduce the amyloid plaques themselves. Sedentary individuals, defined as those taking fewer than 3,000 steps daily, exhibited the most rapid accumulation of tau tangles and a quicker decline in memory and thinking skills over the study period. Tau proteins are more directly associated with cognitive and functional decline and typically appear later in the disease's progression.

This study builds on previous research, including a large 2022 UK study that also connected physical activity to a reduced risk of dementia, partly attributing this to improved cardiovascular health. Dr. Chhatwal noted that these findings suggest lifestyle factors can influence the earliest stages of Alzheimer's and potentially slow the emergence of cognitive symptoms with early intervention.

What we could not confirm